Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 67398 | 4.525 |
09:34 ET | 45668 | 4.485 |
09:36 ET | 22400 | 4.465 |
09:38 ET | 71827 | 4.53 |
09:39 ET | 45228 | 4.505 |
09:41 ET | 45973 | 4.49 |
09:43 ET | 8732 | 4.485 |
09:45 ET | 15717 | 4.485 |
09:48 ET | 8356 | 4.49 |
09:50 ET | 14227 | 4.485 |
09:52 ET | 22456 | 4.475 |
09:54 ET | 21915 | 4.49 |
09:56 ET | 12596 | 4.485 |
09:57 ET | 7329 | 4.48 |
09:59 ET | 10705 | 4.49 |
10:01 ET | 9168 | 4.485 |
10:03 ET | 6538 | 4.5 |
10:06 ET | 50275 | 4.485 |
10:08 ET | 20288 | 4.48 |
10:10 ET | 29461 | 4.485 |
10:12 ET | 10925 | 4.5 |
10:14 ET | 29875 | 4.52 |
10:15 ET | 36054 | 4.495 |
10:17 ET | 4219 | 4.51 |
10:19 ET | 49897 | 4.51 |
10:21 ET | 21476 | 4.51 |
10:24 ET | 27730 | 4.52 |
10:26 ET | 17615 | 4.515 |
10:28 ET | 20245 | 4.535 |
10:30 ET | 6782 | 4.545 |
10:32 ET | 21170 | 4.54 |
10:33 ET | 20474 | 4.55 |
10:35 ET | 3020 | 4.540576 |
10:37 ET | 20667 | 4.5244 |
10:39 ET | 3312 | 4.525 |
10:42 ET | 839 | 4.525 |
10:44 ET | 35643 | 4.525 |
10:46 ET | 400 | 4.525 |
10:48 ET | 26996 | 4.535 |
10:50 ET | 16089 | 4.52 |
10:51 ET | 9528 | 4.535 |
10:53 ET | 14228 | 4.525 |
10:55 ET | 12027 | 4.51 |
10:57 ET | 6504 | 4.52 |
11:00 ET | 34050 | 4.505 |
11:02 ET | 15707 | 4.4999 |
11:04 ET | 900 | 4.49 |
11:06 ET | 2948 | 4.49 |
11:08 ET | 8730 | 4.495 |
11:09 ET | 28456 | 4.495 |
11:11 ET | 3548 | 4.5 |
11:13 ET | 44994 | 4.49 |
11:15 ET | 3557 | 4.48 |
11:18 ET | 9543 | 4.49 |
11:20 ET | 5350 | 4.4879 |
11:22 ET | 7784 | 4.495 |
11:24 ET | 9682 | 4.485 |
11:26 ET | 10112 | 4.49 |
11:27 ET | 12109 | 4.485 |
11:29 ET | 7300 | 4.485 |
11:31 ET | 8729 | 4.485 |
11:33 ET | 8177 | 4.485 |
11:36 ET | 5764 | 4.49 |
11:38 ET | 25079 | 4.485 |
11:40 ET | 900 | 4.48 |
11:42 ET | 1025 | 4.48 |
11:44 ET | 4259 | 4.485 |
11:45 ET | 38182 | 4.485 |
11:47 ET | 1549 | 4.48 |
11:49 ET | 28767 | 4.485 |
11:51 ET | 100 | 4.485 |
11:54 ET | 4717 | 4.485 |
11:56 ET | 1184 | 4.485 |
11:58 ET | 2824 | 4.485 |
12:00 ET | 2811 | 4.4825 |
12:02 ET | 4728 | 4.48 |
12:03 ET | 608 | 4.485 |
12:05 ET | 20818 | 4.48 |
12:07 ET | 12261 | 4.475 |
12:09 ET | 2089 | 4.475 |
12:12 ET | 1400 | 4.475 |
12:14 ET | 1048 | 4.475 |
12:16 ET | 41436 | 4.48 |
12:18 ET | 27756 | 4.485 |
12:20 ET | 9034 | 4.49 |
12:21 ET | 400 | 4.4979 |
12:23 ET | 6021 | 4.485 |
12:25 ET | 2763 | 4.485 |
12:27 ET | 400 | 4.49 |
12:30 ET | 16369 | 4.495 |
12:32 ET | 6460 | 4.4951 |
12:34 ET | 556 | 4.49 |
12:36 ET | 6075 | 4.505 |
12:38 ET | 11103 | 4.4968 |
12:39 ET | 20169 | 4.52 |
12:41 ET | 9022 | 4.515 |
12:43 ET | 26420 | 4.525 |
12:45 ET | 27923 | 4.51 |
12:48 ET | 14194 | 4.515 |
12:50 ET | 100 | 4.515 |
12:52 ET | 9390 | 4.5 |
12:54 ET | 29810 | 4.49 |
12:56 ET | 24299 | 4.494 |
12:57 ET | 13152 | 4.485 |
12:59 ET | 5922 | 4.48 |
01:01 ET | 6522 | 4.485 |
01:03 ET | 35284 | 4.5 |
01:06 ET | 22512 | 4.51 |
01:08 ET | 10032 | 4.515 |
01:10 ET | 604 | 4.515 |
01:12 ET | 5506 | 4.505 |
01:14 ET | 500 | 4.5 |
01:15 ET | 1306 | 4.5 |
01:17 ET | 500 | 4.5 |
01:19 ET | 2558 | 4.5 |
01:21 ET | 47451 | 4.495 |
01:26 ET | 12694 | 4.495 |
01:28 ET | 48440 | 4.4911 |
01:30 ET | 34752 | 4.5 |
01:32 ET | 1963 | 4.505 |
01:33 ET | 7677 | 4.505 |
01:35 ET | 5061 | 4.49 |
01:37 ET | 4376 | 4.495 |
01:39 ET | 871 | 4.49 |
01:42 ET | 18299 | 4.48 |
01:44 ET | 6732 | 4.48 |
01:46 ET | 2064 | 4.485 |
01:48 ET | 5475 | 4.484567 |
01:50 ET | 4658 | 4.485 |
01:51 ET | 25457 | 4.485 |
01:53 ET | 2000 | 4.485 |
01:55 ET | 12868 | 4.495 |
01:57 ET | 25225 | 4.48 |
02:00 ET | 400 | 4.485 |
02:02 ET | 24390 | 4.485 |
02:04 ET | 350 | 4.4899 |
02:06 ET | 100 | 4.485 |
02:08 ET | 2073 | 4.49 |
02:09 ET | 6396 | 4.48 |
02:11 ET | 1808 | 4.49 |
02:13 ET | 27882 | 4.49 |
02:15 ET | 7642 | 4.485 |
02:18 ET | 3556 | 4.485 |
02:20 ET | 1352 | 4.48 |
02:22 ET | 8475 | 4.49 |
02:24 ET | 1800 | 4.485 |
02:26 ET | 84164 | 4.505 |
02:27 ET | 28104 | 4.5035 |
02:29 ET | 10104 | 4.51 |
02:31 ET | 51313 | 4.5 |
02:33 ET | 21328 | 4.485 |
02:36 ET | 1199 | 4.485 |
02:38 ET | 415 | 4.49 |
02:40 ET | 3300 | 4.4871 |
02:42 ET | 27888 | 4.49 |
02:44 ET | 8710 | 4.495 |
02:45 ET | 1801 | 4.495 |
02:47 ET | 7537 | 4.49 |
02:49 ET | 21738 | 4.48 |
02:51 ET | 29387 | 4.485 |
02:54 ET | 5488 | 4.485 |
02:56 ET | 3622 | 4.485 |
02:58 ET | 23054 | 4.485 |
03:00 ET | 22507 | 4.495 |
03:02 ET | 10647 | 4.485 |
03:03 ET | 48348 | 4.475 |
03:05 ET | 300 | 4.48 |
03:07 ET | 16847 | 4.48 |
03:09 ET | 531 | 4.49 |
03:12 ET | 8445 | 4.485 |
03:14 ET | 17117 | 4.495 |
03:16 ET | 44571 | 4.5 |
03:18 ET | 17194 | 4.5 |
03:20 ET | 11940 | 4.495 |
03:21 ET | 7807 | 4.485 |
03:23 ET | 9361 | 4.485 |
03:25 ET | 2037 | 4.485 |
03:27 ET | 41193 | 4.49 |
03:30 ET | 10601 | 4.495 |
03:32 ET | 25870 | 4.51 |
03:34 ET | 2818 | 4.51 |
03:36 ET | 2316 | 4.505 |
03:38 ET | 2866 | 4.505 |
03:39 ET | 2970 | 4.51 |
03:41 ET | 2523 | 4.505 |
03:43 ET | 10248 | 4.51 |
03:45 ET | 6591 | 4.505 |
03:48 ET | 26588 | 4.505 |
03:50 ET | 35276 | 4.52 |
03:52 ET | 11754 | 4.52 |
03:54 ET | 147132 | 4.5 |
03:56 ET | 121567 | 4.5 |
03:57 ET | 45664 | 4.51 |
03:59 ET | 1124240 | 4.51 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.8B | -12.5x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.5x | --- |
Celldex Therapeutics Inc | 2.7B | -13.1x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -13.9x | --- |
Vera Therapeutics Inc | 2.6B | -20.4x | --- |
Structure Therapeutics Inc | 2.5B | -18.7x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | 2,019.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.